SPONSOR
Hebei Medical University Fourth Hospital
Total Trials
8
Recruiting
8
Phases
Phase 2, Phase 4
Conditions studied: Breast CancerPancreatic CancerEsophageal Squamous Cell CarcinomaRectal CancerNon-small Cell Lung CancerMalignant NeoplasmOrgan DamageHER2-positive Breast CancerAdvanced Breast Cancer
NCT06107673 Phase 2
Recruiting
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Breast Cancer
NCT06435260 Phase 2
Recruiting
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Pancreatic Cancer
NCT05578053
Recruiting
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
Breast Cancer
NCT03964753 Phase 2
Recruiting
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
NCT06210971 Phase 2
Recruiting
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Rectal Cancer
NCT05241028 Phase 2
Recruiting
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
NCT07131007
Recruiting
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Malignant Neoplasm
NCT06217185 Phase 4
Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
HER2-positive Breast Cancer